Blueprint Medicines Accounts Payable 2014-2025 | BPMC

Blueprint Medicines accounts payable for the quarter ending March 31, 2025 were $1M, a 83.76% decline year-over-year.

  • Blueprint Medicines accounts payable for 2024 were $0.007B, a 44.16% increase from 2023.
  • Blueprint Medicines accounts payable for 2023 were $0.005B, a 72.59% increase from 2022.
  • Blueprint Medicines accounts payable for 2022 were $0.003B, a 67.25% decline from 2021.

Blueprint Medicines Accounts Payable 2014-2025 | BPMC

  • Blueprint Medicines accounts payable for 2024 were $0.007B, a 44.16% increase from 2023.
  • Blueprint Medicines accounts payable for 2023 were $0.005B, a 72.59% increase from 2022.
  • Blueprint Medicines accounts payable for 2022 were $0.003B, a 67.25% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$217.3B
Amgen (AMGN)$160.8B
Gilead Sciences (GILD)$136.6B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$96B
CSL (CSLLY)$78.5B
GSK (GSK)$78.4B
Regeneron Pharmaceuticals (REGN)$59.2B
Alnylam Pharmaceuticals (ALNY)$42.1B
Argenex SE (ARGX)$35.4B
BioNTech SE (BNTX)$27B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.8B
Biogen (BIIB)$18.8B
Illumina (ILMN)$15.3B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$14B
Incyte (INCY)$13.4B
Moderna (MRNA)$12.4B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exact Sciences (EXAS)$10.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.1B
Roivant Sciences (ROIV)$7.8B
Regencell Bioscience Holdings (RGC)$7.6B
Legend Biotech (LEGN)$7.3B